Scientists Found A Cheaper Way To Catch Lung Cancer Early, And It Skips DNA Sequencing

This Blood Test Hunts Lung Cancer With Light Instead

Lung cancer kills more people worldwide than any other cancer, and a big reason for that grim statistic is that it is often caught too late. Screening tools exist, but the tests used to confirm or monitor the disease can be expensive, slow, or require highly specialized lab equipment. A new approach published in the journal npj Precision Oncology may offer a faster, cheaper path forward, and it works without the DNA sequencing used by many methylation-based liquid biopsy approaches.

Researchers developed a method that reads chemical flags on DNA floating freely in a person’s blood, a type of genetic material known as cell-free DNA. Cancer cells leave behind detectable traces in the bloodstream, and scientists have long known that the pattern of these chemical flags, called methylation marks, looks different in cancer patients than in healthy people. What sets this new approach apart is how it reads those marks: instead of sequencing the DNA, the method uses an engineered protein to fluorescently label methylated spots across the genome, then reads the resulting pattern on a standard microarray chip.

In a proof-of-concept study involving 103 participants, the researchers trained a classifier on part of the group, then tested it on a separate, blinded set of 60 people: 29 with lung cancer, 31 healthy controls. In that blinded test, the approach reached 93.1% sensitivity and 90.3% specificity for stage 2 through stage 4 lung cancer. The authors caution that specificity may run lower in practice, since the test would also need to tell cancer apart from benign lung conditions, not just from healthy people. Still, for researchers seeking simpler ways to detect lung cancer from blood, that performance is worth testing at a larger scale, especially in earlier-stage disease.

Methylation Marks Shift When Lung Cells Turn Cancerous

Every cell in the human body carries DNA, and layered on top of the genetic code itself is a system of chemical marks that help control how genes switch on or off. One of the most studied of these marks is methylation, a small chemical tag attaching to specific spots along the DNA strand.

When cells become cancerous, methylation patterns go haywire. Marks appear where they should not and disappear from where they should. Because dying tumor cells shed DNA fragments into the bloodstream, a blood draw can reveal whether those abnormal patterns are present. Researchers call this a liquid biopsy, a cancer test done through blood rather than a tissue sample cut from the body.

Reading methylation patterns at the level of detail needed for reliable cancer detection has typically required DNA sequencing, a process that is expensive, slow, and dependent on specialized lab infrastructure. That has limited how widely these tests can be used, particularly in lower-resource settings.

A Fluorescent Highlighter Replaces DNA Sequencing

This team’s approach chemically treats the DNA sample to make its methylation marks readable, then uses an engineered enzyme to attach a fluorescent label to every originally methylated spot. It works something like a molecular highlighter for methylated DNA. Researchers then look for patterns that differ between cancer patients and healthy people, using 170 genomic regions selected during training for showing the sharpest contrast.

Once labeled, the DNA is placed on a microarray chip that captures specific DNA fragments and measures the fluorescent signal coming off them, using commercially available microarray technology rather than a sequencing platform. The researchers estimate the current laboratory version takes two to three days and costs about $60 per sample when run in batches of two dozen. No sequencing machine is required.

The Test Has Not Yet Faced Its Toughest Challenges

Whether the approach holds up at stage 1 remains an open question. Early tumors shed far less DNA into the blood than advanced ones, which is part of why liquid biopsies in general struggle most at the stage when catching cancer would help the most.

Treatment monitoring was also explored in two patients with advanced lung cancer, offering very preliminary evidence that the methylation signal may track how a tumor responds to therapy. One patient’s cancer shrank after treatment, and that patient’s methylation profile shifted toward the pattern seen in healthy people. The other patient’s cancer did not respond, and the methylation profile stayed largely unchanged. With only two cases, this is far from proof, but it points toward repeat testing eventually giving doctors another way to track treatment response alongside imaging such as CT or PET scans.

Larger Trials, Not a Clinical Test, Are the Next Step

With 103 participants, the data is promising, but larger trials across more diverse populations are needed before this test could enter routine medical practice. Several of the researchers have financial ties to JaxBio Technologies LTD, the spinout company that has licensed the technology, a common path for moving lab discoveries toward commercial use. A pending patent application covers the method.

A blood test that is fast, cheap, and skips specialized sequencing equipment could eventually change who gets screened for lung cancer and how often. This study does not prove that yet, but it offers a working method and results specific enough to justify testing the idea at a larger scale.

---

Disclaimer: This article describes early-stage research and is intended for informational purposes only. It is not medical advice. Anyone with questions about lung cancer screening or diagnosis should speak with a qualified healthcare provider.

---

---